FDA: Industry’s Failure To Follow Guidance Increases 510(k) Review Times
This article was originally published in The Gray Sheet
Executive Summary
The top reason FDA sends two or more requests for information during 510(k) reviews is because firms failed to follow guidance or recognized standards, said Christy Foreman, acting director of FDA’s Office of Device Evaluation.
You may also be interested in...
Shuren On The Hill: Industry Should Take More Blame For Review Delays
CDRH Director Jeffrey Shuren called out industry during a Feb. 17 House subcommittee hearing for playing a significant role in causing delays in pre-market device reviews.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.